Clinical Trial Update: Efficacy of Sr-89 for Differentiated Thyroid Cancer With Bone Metastases [Phase 4]

View source ↗

Summary

Phase 4 trial update on the efficacy of Strontium-89 (Sr-89) for differentiated thyroid cancer with bone metastases.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Metastases
• Differentiated Thyroid Cancer

Drugs mentioned

• Sr-89 (strontium-89)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Thyroid Neoplasm Follicular, Bone Metastases | Phase 4 | Status: UNKNOWN